RxDoctor Payments Data

Ronald Cathcart, MD

Internal Medicine · Melbourne, FLNPI 1134142003

Payments from drug & device makers

$150,467in general payments, 2019–2025

Across 294 payments — averaging $511.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$149K
  • Viiv Healthcare Company$764
  • Janssen Products, LP$185
  • Merck$94
  • Theratechnologies Inc.$72
  • Johnson & Johnson$59
  • plus $60 from 3 others

What the payments were for

  • Consulting fees$5,2403%
  • Speaking & faculty fees$113,32375%
  • Travel & lodging$25,58717%
  • Food & beverage$6,1864%
  • Education$1310%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$150,467 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$30,731
Medicare patients
81
Services billed
379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala1,591$6,202,801
TivicayDolutegravir Sodium208$568,151
PrezcobixDarunavir/Cobicistat141$350,618
JulucaDolutegravir/Rilpivirine101$339,772
TriumeqAbacavir/Dolutegravir/Lamivudi61$204,636
DovatoDolutegravir Sodium/Lamivudine45$138,142
GenvoyaElviteg/Cob/Emtri/Tenof Alafen30$118,725
DescovyEmtricitabine/Tenofov Alafenam31$69,639
Darunavir33$50,325
EvotazAtazanavir Sulfate/Cobicistat23$38,975
IsentressRaltegravir Potassium11$24,189
TruvadaEmtricitabine/Tenofovir (Tdf)13$24,079
PrezistaDarunavir16$20,729
ReyatazAtazanavir Sulfate13$18,946
EliquisApixaban32$18,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy, Truvada$149,234$6,415,2431,665 claims
Viiv Healthcare CompanyTivicay, Juluca, Triumeq, Dovato$764$1,250,701415 claims
Johnson & JohnsonPrezcobix$59$350,618141 claims
MerckIsentress$94$24,18911 claims
Janssen Scientific Affairs, LLCPrezista$12$20,72916 claims
AbbVieNorvir$12$2,72912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →